Pharma Mar | PHM - Cash And Equivalent


Pharma Mar reported EUR48.86M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Moderna USD 1.91B 687M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Pharma Mar EUR 48.86M 31.05M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026